Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Anlotinib + Osimertinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Anlotinib||AL3818|AL-3818|AL 3818||FGFR Inhibitor (Pan) 25 KIT Inhibitor 56 PDGFR Inhibitor (Pan) 30 RET Inhibitor 52 VEGFR2 Inhibitor 37 VEGFR3 Inhibitor 6||Anlotinib (AL-3818) inhibits KDR (VEGFR2) and VEGFR3, FGFR1-4, PDGFRA/B, KIT, and RET, which may inhibit angiogenesis and tumor cell growth (PMID: 27716285, PMID: 32547218, PMID: 32724339).|
|Osimertinib||Tagrisso||AZD9291||EGFR Inhibitor 3rd gen 26||Tagrisso (osimertinib) is a third-generation EGFR inhibitor that selectively binds mutant forms of the EGF receptor, inhibiting downstream signaling and potentially reducing cell proliferation and growth in EGFR overexpressing tumors (PMID: 29151359). Tagrisso (osimertinib) is FDA-approved for use as adjuvant therapy after resection in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or L858R, as first-line therapy in patients with metastatic NSCLC harboring EGFR exon 19 deletion or L858R, and for treatment in patients with metastatic NSCLC harboring EGFR T790M whose disease progressed after EGFR TKI therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|AXL over exp||lung non-small cell carcinoma||sensitive||Anlotinib + Osimertinib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the combination of Anlotinib (AL-3818) and Tagrisso (osimertinib) inhibited proliferation and viability in Tagrisso (osimertinib)-resistant non-small cell lung cancer cell lines with overexpression of AXL in culture, and inhibited tumor growth in cell line xenograft models (PMID: 36681369).||36681369|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|